Full Text CA-96-009 IMMUNOBIOLOGY OF AIDS LYMPHOMA NIH GUIDE, Volume 25, Number 8, March 15, 1996 RFA: CA-96-009 P.T. 34 Keywords: Immunology Cancer/Carcinogenesis AIDS National Cancer Institute Letter of Intent Receipt Date: April 25, 1996 Application Receipt Date: May 24, 1996 PURPOSE The intent of this initiative is to stimulate research on biologic and immunologic mechanisms involved in the development of lymphomas in AIDS patients. Specifically, this initiative will encourage development and testing of hypotheses about the mechanisms of lymphomagenesis in the unique immune environment induced by HIV infection. This environment is characterized by defects in immune regulation, loss of specific immune cell subsets, presence of abnormal cytokine levels, changes in the architecture of germinal centers and other lymphoid tissues and an apparent loss of immune surveillance. Any or all of these factors may play a role in the high incidence and distinctive characteristics of AIDS-associated lymphoma. This dysregulation may lead to an increase in the rate of generation of transformed lymphocytes and/or to enhanced capacity of these cells to escape surveillance and cause disease. Before effective therapies can be designed, it is necessary to understand the basic mechanism of lymphomagenesis in AIDS. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This Request for Applications (RFA), Immunobiology of AIDS Lymphoma, is related to the priority area of cancer. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by foreign and domestic, for-profit and non-profit organizations, public and private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as principal investigators. MECHANISM OF SUPPORT Support of this program will be through the National Institutes of Health (NIH) research project grant (R01). Applicants will be responsible for the planning, direction, and execution of the proposed project. Awards will be administered under PHS grants policy as stated in the Public Health Service Grants Policy Statement DHHS Publication No. (OASH) 90-50,000, revised April 1, 1994. This RFA is a one-time solicitation. Generally, future unsolicited competing renewal applications will compete with all investigator-initiated R01 applications and be reviewed according to the customary peer review procedures by the Division of Research Grants (DRG). However, should the NCI determine that there is a sufficient continuing program need, a request for renewal applications will be announced. FUNDS AVAILABLE Approximately $1,000,000 in total costs per year for four years will be committed to fund applications that are submitted in response to this RFA. It is estimated that the average amount of the direct costs for each award will be $150,000. It is anticipated that approximately six individual R01 grant awards will be made. This level of support is dependent on the receipt of a sufficient number of applications of high scientific merit. Because the nature and scope of the research proposed in response to this RFA may vary, it is anticipated that the size of an award may vary also. The earliest start date for the initial award will be September 24, 1996. Although this program is provided for in the financial plans of the NCI, awards pursuant to this RFA are contingent upon the availability of funds for this purpose. RESEARCH OBJECTIVES Background The incidence of Non-Hodgkin's Lymphoma (NHL) has increased steadily during the past decade, with the most dramatic increase occurring in the AIDS associated B-cell lymphomas. As AIDS patients are living longer, NHL has emerged as a major clinical problem in AIDS. The causes of this are poorly understood. Yet, during the same decade, tremendous progress was made in elucidating mechanisms of B and T lymphocyte regulation in both normal and immunodeficient patients. Initially, the emphasis was focused on elucidating the cellular and molecular mechanisms that govern the function of the immune system in normal individuals. Comparisons have been made between immune mechanisms in non-immunodeficient and immunodeficient individuals. It is obvious that deficiencies in the functioning components of the immune system, e.g., B or T cells, could readily account for the lack of resistance to infectious diseases in immunodeficient animals and patients. But no such explanation is readily available to explain the etiology and pathogenesis of AIDS-associated lymphomas. Studies have shown that similar immune abnormalities exist among congenitally immunodeficient, iatrogenically suppressed and AIDS patients. For example, low numbers of CD4+ T cells can be found in the peripheral circulation of all three groups of patients. Similarly, abnormal cytokine levels are detected in both non-AIDS and AIDS patients. This is best exemplified by high levels of interleukin 6 (IL-6) detected in the common-variable immunodeficiency (CVI) syndrome and AIDS patients. This apparently reflects lack of normal B cell function in both groups of patients. However, other studies have shown distinct differences between AIDS patients and patients with other immunodeficiencies. For example, Epstein-Barr Virus (EBV) was reported to induce essentially all of the B lymphomas in post-transplant recipients whereas EBV appears to play a lesser role in some AIDS-associated lymphomas. Other studies indicated that HIV and other retroviruses do not play a direct role in inducing AIDS lymphomas. The NCI-sponsored workshop entitled "Biology of AIDS Lymphoma," held in Bethesda in May 1992, provided a forum for discussing the current state of research into the biologic and immunologic mechanisms that underlie the development of AIDS lymphoma. There was general agreement that while AIDS lymphoma is a heterogeneous collection of diseases, there are unique features that distinguish AIDS lymphomas from lymphomas in other immunodeficiency states and lymphomas in the general population. Participants identified numerous factors that might contribute to the unique pattern of lymphomagenesis, but no consensus was possible at the current state of knowledge on a mechanistic model for AIDS lymphoma development. On one level, the factors that lead to lymphomagenesis in AIDS are understandable, but the data that support this understanding are largely correlative and details are lacking. Factors that have been suggested to play a role in AIDS lymphomagenesis include, but are not limited to, loss of immune surveillance, infection by EBV and other viruses, chronic antigenic stimulation, high levels of stimulatory cytokines (such as IL-6), low levels of inhibitory cytokines, oncogene activation, other increases in DNA damage and alterations in DNA repair mechanisms. For every factor, important questions remain unanswered and will remain so until incisive, mechanistic studies are undertaken. Special Requirements Applicants should understand that the focus of this initiative is on the basic mechanisms leading to lymphomagenesis in AIDS patients. Thus, studies designed to test new forms of immunotherapy or other treatment modalities for AIDS lymphoma are outside the scope of this initiative. Thus, applications with a primary focus on designing new treatments for AIDS lymphoma will not be considered responsive to this initiative and will be returned to the applicant. It is anticipated that the majority of applications submitted in response to this RFA will propose experiments requiring access to cells and/or tissues from AIDS patients. Because such patient material is not readily available, applicants who propose such experiments must document that they have adequate access to these resources to carry out the proposed studies. Applicants who do not demonstrate this access will have their applications returned without review. The intent of this RFA is to elucidate the mechanisms underlying lymphomagenesis in AIDS patients. While the most direct route to understanding these mechanisms is to study AIDS patients or patient-derived material, it is recognized that studies of animal models of AIDS lymphoma or studies involving comparison to lymphomagenesis in other human immunodeficiency states may yield important insights into relevant mechanisms. Such studies might be designed to shed light on factors such as abnormal cytokine production in immunodeficient individuals, CD4+ T cell depletion and subsequent effects on B cell lymphomagenesis, the overall immune dysfunction in B and T cells and effects on dendritic cells, B cell lymphomagenesis in immunodeficient individuals, post-transplant lymphoproliferative disease (PTLD) and lymphomagenesis, immune surveillance and malignant B cell proliferation, the role of HIV-infected follicular dendritic cells within germinal centers, the germinal center microenvironment and immunoregulatory effects on B cells and the role of chronic polyclonal B-cell stimulation in lymphoma development. Studies primarily involving animal models of AIDS or humans with immunodeficiency states other than AIDS will be considered responsive only if the intent is to derive a testable hypothesis concerning lymphomagenesis in AIDS patients and if the application contains a clear and compelling plan to apply the results obtained in a direct study of AIDS lymphoma. It is clear that the Epstein-Barr virus (EBV) plays a predominant role in lymphomagenesis in post-transplant recipients and a somewhat lesser, but still major, role in AIDS lymphomagenesis. However, the direct involvement of EBV and/or retroviruses in AIDS lymphomagenesis was the subject of a previous NCI RFA (RFA CA 90-15). Therefore, applications where the sole focus is on EBV-induced or retrovirus-induced lymphomagenesis in iatrogenically immunosuppressed individuals (animals or humans) will not be considered responsive to this initiative and these applications will be returned. However, studies that include, but are not limited to, retroviral-oncogene activation of immune cells or retroviral models of AIDS employing naturally occurring immunodeficient individuals where the intent is to derive a testable hypothesis of lymphomagenesis with application to the human disease will be considered responsive to the initiative. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. Investigators proposing research involving human subjects should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. LETTER OF INTENT Prospective applicants are asked to submit, by April 25, 1996 a letter of intent that includes a descriptive title of the proposed research, the name, address and telephone number of the Principal Investigator, the identities of other key personnel and participating institutions, and the number and title of the RFA in response to which the application is being submitted. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information that it contains is helpful in planning for the review of applications. It allows NCI staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to: Dr. John F. Finerty Division of Cancer Biology, Diagnosis, and Centers National Cancer Institute Executive Plaza North, Room 501 6130 Executive Boulevard Rockville, MD 20892-9904 Telephone: (301) 496-7815 FAX: (301) 496-8656 Email: fin@nih.gov APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 5/95) is to be used in applying for these grants. Applications kits are available at most institutional offices of sponsored research and may be obtained from the Grants Information Office, Office of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone 301/710-0267, email: girg@drgpo.drg.nih.gov. The RFA label available in the PHS 398 (rev.5/95) application form must be affixed to the bottom of the face page of the application. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title and number must be typed on line 2 of the face page of the application form and the YES box must be marked. Submit a signed, typewritten original of the application, including the Checklist, and three signed, single-sided photocopies, in one package with the appendices to: DIVISION OF RESEARCH GRANTS NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for express/courier service) At the time of submission, two additional copies of the application must also be sent to: Ms. Toby Friedberg Division of Extramural Activities National Cancer Institute Executive Plaza North, Suite 636 6130 Executive Boulevard-MSC 7405 Bethesda, MD 20892-7405 (if using U.S. Postal Service) Rockville, MD 20852 (if hand delivered or delivery service) Applications must be received by May 24, 1996. If an application is received after that date, it will be returned to the applicant without review. The Division of Research Grants (DRG) will not accept any application in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The DRG will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed for completeness by DRG and responsiveness by the NCI. Incomplete applications will be returned to the applicant without further consideration. If the application is not responsive to the RFA, NCI staff may contact the applicant to determine whether to return the application to the applicant or submit it for review in competition with unsolicited applications at the next review cycle. Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by an appropriate peer review group convened by the NCI in accordance with the review criteria stated below. As part of the initial review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of applications under review, will be discussed, assigned a priority score, and receive a second level of review by the National Cancer Advisory Board. Review criteria o scientific, technical, or medical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o where applicable, appropriateness of the model system chosen for the experiments proposed and potential relevance of the model system to AIDS lymphoma; o qualifications and research experience of the Principal Investigator and staff, particularly, but not exclusively, in the area of the proposed research; o demonstration of availability and access to appropriate human tissue necessary to perform the proposed research; o where applicable, availability of clinical information associated with human samples; o availability of the resources necessary to perform the research; o appropriateness of the proposed budget and duration in relation to the proposed research; o Adequacy of plans to include both genders and minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. The initial review group will also examine the provisions for the protection of human and animal subjects and the safety of the research environment, the safety of the research environment, and conformance with the NIH guidelines for the Inclusion of Women and Minorities as Subjects in Clinical Research. AWARD CRITERIA The earliest anticipated date of award is September 24, 1996. Awards will be made on the basis of priority score and funds available. In addition to technical merit of the application, the NCI will consider how well the proposed research meets the goals and objectives of the program as described in the RFA, as well as the level of total cost requested. Only highly-rated projects will be funded. INQUIRIES Inquiries concerning this RFA are encouraged. The opportunity to clarify any issue or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Dr. John F. Finerty Division of Cancer Biology National Cancer Institute Executive Plaza North, Room 501 6130 Executive Boulevard Rockville, MD 20892-9904 Telephone: (301) 496-7815 FAX: (301) 496-8656 Email: fin@nih.gov Direct inquiries regarding fiscal matters to: Ms. Sara Stone Grants Management Branch National Cancer Institute Executive Plaza South, Room 243 Bethesda, MD 20892 Telephone: (301) 4976-7800 x266 Email: Stones@GAB.NCI.NIH.gov AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance No. 93.396. Awards are made under authorization of the Public Health Service Act, Title IV, Part A (Public Law 78-410, as amended by Public Law 99-158, 42 USC 241 and 285) and administered under PHS grants policies and Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems Agency review. The PHS strongly encourages all grant recipients to provide a smoke-free workplace and promote the nonuse of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |